Pharmaceutical firm Eisai Co. and its joint venture with Italy’s Bracco SpA said Monday they will withdraw a new drug application for the contrast agent code-named E7155.

The decision was made because additional clinical data are necessary to complete the risk/benefit profile, Eisai and Bracco-Eisai Co. said in a joint statement.

E7155 is a gadolinium-based contrast agent for magnetic resonance imaging, which was licensed from Bracco Imaging SpA, the two companies said.

They said they are discussing a development plan for the product, which is currently being marketed in other countries.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.